Aspen Strong like Russia. But not too strong
Aspen’s results were in last week, and erred on the side of downbeat … only kidding, of course! Revenue up 27% to R19.3billion and something called EBIDTA (which we thought was something only a pill from Aspen could cure) was up 11% to R2billion for the domestic business on sales of R7.4billion. The big earner was its Asia Pacific division, at R7.6billion of the revenue and EBITDA up 30% to R1.9billion. But wait, there’s more! Thanks to fairly complex deals with drugmakers MSD and GlaxoSmithKline, which has still failed to find a cure for bad punctuation, Aspen will inherit a team of 450 new reps, 150 of whom will be in Russia. With its burgeoning yet cost-conscious middle class, this is exactly the sort of place where Aspen swims like a barracuda among the catfish, or something.
Comment: So expect more fireworks, and more mixed metaphors, to come.